4/14
12:18 pm
idya
IDEAYA Biosciences (IDYA) had its price target raised by The Goldman Sachs Group, Inc. from $31.00 to $35.00. They now have a "neutral" rating on the stock.
Low
Report
IDEAYA Biosciences (IDYA) had its price target raised by The Goldman Sachs Group, Inc. from $31.00 to $35.00. They now have a "neutral" rating on the stock.
4/14
11:10 am
idya
IDEAYA Biosciences (IDYA) had its price target raised by Wells Fargo & Company from $44.00 to $48.00. They now have an "overweight" rating on the stock.
Low
Report
IDEAYA Biosciences (IDYA) had its price target raised by Wells Fargo & Company from $44.00 to $48.00. They now have an "overweight" rating on the stock.
4/14
09:47 am
idya
IDEAYA Biosciences (IDYA) had its price target raised by Wedbush from $52.00 to $58.00. They now have an "outperform" rating on the stock.
Medium
Report
IDEAYA Biosciences (IDYA) had its price target raised by Wedbush from $52.00 to $58.00. They now have an "outperform" rating on the stock.
4/14
09:12 am
idya
IDEAYA Biosciences (IDYA) had its price target raised by Guggenheim from $50.00 to $54.00. They now have a "buy" rating on the stock.
Medium
Report
IDEAYA Biosciences (IDYA) had its price target raised by Guggenheim from $50.00 to $54.00. They now have a "buy" rating on the stock.
4/14
08:57 am
idya
IDEAYA Biosciences (IDYA) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
Low
Report
IDEAYA Biosciences (IDYA) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
4/14
01:22 am
idya
IDEAYA Biosciences Unveils OptimUM-02 Data: Darovasertib/Crizotinib Doubles PFS in Uveal Melanoma [Yahoo! Finance]
Low
Report
IDEAYA Biosciences Unveils OptimUM-02 Data: Darovasertib/Crizotinib Doubles PFS in Uveal Melanoma [Yahoo! Finance]
4/13
04:08 pm
idya
IDEAYA Biosciences (IDYA) was given a new $65.00 price target by Truist Financial Corporation.
Low
Report
IDEAYA Biosciences (IDYA) was given a new $65.00 price target by Truist Financial Corporation.
4/13
06:00 am
idya
IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Metastatic Uveal Melanoma
High
Report
IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Metastatic Uveal Melanoma
4/10
04:05 pm
idya
IDEAYA Biosciences to Announce Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026
Medium
Report
IDEAYA Biosciences to Announce Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026
4/6
06:15 am
idya
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer [Yahoo! Finance]
Low
Report
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer [Yahoo! Finance]
4/6
06:06 am
idya
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer [TheStreet.com]
Low
Report
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer [TheStreet.com]
4/6
06:00 am
idya
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer
Low
Report
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer
4/4
05:30 am
idya
Why IDEAYA Biosciences (IDYA) Is Up 7.5% After Early Data From First-in-Class Cancer Combo [Yahoo! Finance]
Low
Report
Why IDEAYA Biosciences (IDYA) Is Up 7.5% After Early Data From First-in-Class Cancer Combo [Yahoo! Finance]
4/3
07:28 pm
idya
A Look At IDEAYA Biosciences (IDYA) Valuation After New DLL3 Combo Trial Progress And Early Responses [Yahoo! Finance]
Low
Report
A Look At IDEAYA Biosciences (IDYA) Valuation After New DLL3 Combo Trial Progress And Early Responses [Yahoo! Finance]
3/31
10:20 am
idya
IDEAYA Biosciences (IDYA) had its "outperform" rating reaffirmed by Wedbush. They now have a $52.00 price target on the stock.
Low
Report
IDEAYA Biosciences (IDYA) had its "outperform" rating reaffirmed by Wedbush. They now have a $52.00 price target on the stock.
3/30
06:13 am
idya
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma [Yahoo! Finance]
Low
Report
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma [Yahoo! Finance]
3/30
06:00 am
idya
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma
Low
Report
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma
3/27
06:00 am
idya
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
3/22
10:14 am
idya
IDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance from Phase 2/3 OptimUM-02 Trial [Yahoo! Finance]
Medium
Report
IDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance from Phase 2/3 OptimUM-02 Trial [Yahoo! Finance]
3/22
10:00 am
idya
IDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance from Phase 2/3 OptimUM-02 Trial
Medium
Report
IDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance from Phase 2/3 OptimUM-02 Trial
3/18
06:13 am
idya
IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs [Yahoo! Finance]
Medium
Report
IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs [Yahoo! Finance]
3/18
06:00 am
idya
IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs
Medium
Report
IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs
3/9
06:22 am
idya
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update [Yahoo! Finance]
Medium
Report
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update [Yahoo! Finance]
3/9
06:00 am
idya
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update
Low
Report
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update
3/6
10:36 am
idya
IDEAYA Biosciences, Inc. (IDYA) Enrolls First Patient in Phase 1 Trial of IDE034 Bispecific ADC [Yahoo! Finance]
Low
Report
IDEAYA Biosciences, Inc. (IDYA) Enrolls First Patient in Phase 1 Trial of IDE034 Bispecific ADC [Yahoo! Finance]